Replies to post #674 on Xenacare Holdings Inc.(fka XCHO)

[alj14]

Stervc,

That comparison with the figures for NEPH is illuminating.

There was very clear positive differentiation in the ASCO report between Cobroxin and Ultram.

alj

[Bakerman_06]

Nice post. I expect to see 20c this week alone.

[art35]

The following drugs were/are for osteo-arthritis suffers i believe----chronic pain yes--but a specific diagnosis pain--

Does our drug fit in here???

The clinical study below conducted by the American Society of Clinical Oncology (ASCO) confirmed that Cobroxin, for chronic pain, is better than Ultram (tramadol hydrochloride) and would be better than Celebrex and Vioxx because of not having the side effects reported from Celebrex and Vioxx:
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=16&abstractID=1762

[ToyotaMR2s]

great post stervc:)

[Chickadee]

Great DD! A large part of my portfolio is in NEPH, which has been doing well. They still have 2 FDA approvals and a DOD contract(s) right around the corner. The stock should exceed $3 shortly, and climb to $5-7 thereafter... giving them a good opportunity to relist back on AMEX.

I noticed XCHO back on 7/25/09 from doing my usual research on hidden gems. At that time, there was hardly any activity... and it appeared as if Xenacare was a dead stock. I kept it on my watch list, for many reasons. Kudos to $heff for bringing so much attention to XCHO. This company is definitely undervalued, with a ton of potential.

I will be looking for an entry point, to buy shares this week.